APBI 2016

• Level of evidence 1A for clinical utility of MammaPrint® in the clinical – high group • C-High/g-Low (48% N+ !) show a 5-yr DMFS >94% (with or without CT) • In the whole population: 14% reduction in CT prescription • In the c-High subgroup: 46% reduction in CT prescription